WallStreetZenWallStreetZen

NASDAQ: STOK
Stoke Therapeutics Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsDividendOwnership

Analyst price target for STOK

Based on 6 analysts offering 12 month price targets for Stoke Therapeutics Inc.
Min Forecast
$12.00+225.2%
Avg Forecast
$22.17+500.73%
Max Forecast
$35.00+848.51%

Should I buy or sell STOK stock?

Based on 6 analysts offering ratings for Stoke Therapeutics Inc.
Buy
Strong Buy
2 analysts 33.33%
Buy
3 analysts 50%
Hold
1 analysts 16.67%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their STOK stock forecasts and price targets.

STOK stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
Cantor Fitzgerald
Top 6%
95
Strong BuyMaintains$14.00+279.40%2023-08-08
Credit Suisse
Bottom 2%
2
BuyReiterates$23.00+523.31%2023-08-08
HC Wainwright & Co.
Bottom 1%
1
BuyReiterates$35.00+848.51%2023-08-08
Needham
Bottom 3%
3
BuyReiterates$25.00+577.51%2023-08-07
Bank of America
Top 11%
90
HoldUpgrades$12.00+225.20%2023-05-01
Canaccord Genuity
Bottom 9%
9
Strong BuyAssumes$24.00+550.41%2023-04-26

1 of 1

Forecast return on equity

Is STOK forecast to generate an efficient return?
Company
N/A
Industry
0.66%
Market
28.71%

Forecast return on assets

Is STOK forecast to generate an efficient return on assets?
Company
N/A
Industry
-0.05%

STOK revenue growth forecast

How is STOK forecast to perform vs Biotechnology companies and vs the US market?
Company
76.8%
Industry
34.31%
Market
8.24%
STOK's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
STOK's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

STOK vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
STOK$3.69$22.17+500.73%Buy
LRMR$3.78$11.83+213.46%Buy
SGMT$7.62$43.33+468.67%Strong Buy
XFOR$0.99$3.67+270.78%Strong Buy
IMMP$1.84$8.50+361.96%Strong Buy
View Top Biotech Stocks

Stoke Therapeutics Stock Forecast FAQ

Is Stoke Therapeutics Stock a good buy in 2023, according to Wall Street analysts?

The consensus among 6 Wall Street analysts covering (NASDAQ: STOK) stock is to Buy STOK stock.

Out of 6 analysts, 2 (33.33%) are recommending STOK as a Strong Buy, 3 (50%) are recommending STOK as a Buy, 1 (16.67%) are recommending STOK as a Hold, 0 (0%) are recommending STOK as a Sell, and 0 (0%) are recommending STOK as a Strong Sell.

If you're new to stock investing, here's how to buy Stoke Therapeutics stock.

What is STOK's forecast return on equity (ROE) for 2023-2026?

(NASDAQ: STOK) forecast ROE is N/A, which is considered weak.

What is STOK's Price Target?

According to 6 Wall Street analysts that have issued a 1 year STOK price target, the average STOK price target is $22.17, with the highest STOK stock price forecast at $35.00 and the lowest STOK stock price forecast at $12.00.

On average, Wall Street analysts predict that Stoke Therapeutics's share price could reach $22.17 by Aug 8, 2024. The average Stoke Therapeutics stock price prediction forecasts a potential upside of 500.73% from the current STOK share price of $3.69.

What is STOK's forecast return on assets (ROA) for 2023-2026?

(NASDAQ: STOK) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of -0.05%.
©2023 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.